1 Executive Summary
1.1 The Pharmaceutical Pain Market Review: Entering a Crucial Period
1.2 Aims, Scope and Format of the Report
2 Introduction to Pain
2.1 What is Pain?
2.1.1 Historical aspects of Pain
2.2 Pain Pathways
2.2.1 WHO Pain Ladder
2.3 Classification and Types of Pain
2.3.1 Acute Pain
2.3.2 Chronic Pain
2.3.2.1 Psychosocial Effects of Chronic Pain
2.3.2.2 The Financial Burden of Chronic Pain
2.3.2.3 Chronic Cancer Pain
2.3.2.4 Breakthrough Cancer Pain
2.4 Neuropathic Pain
2.4.1 Distinguishing Neuropathic Pain
2.5 Neurochemistry of Pain
2.5.1 Prostaglandins
2.5.2 Opioids
2.6 Pain Treatments
2.7 OTC Pain Relievers
3 An Overview of the Global Pain Pharmaceutical Market 2008-2023
3.1 The Global Pain Pharmaceutical Market Analysis
3.1.1 Celebrex Currently Leads the Pain Pharma Market
3.1.2 The Non-Narcotics Segment Currently Dominates the Pain Market - But Will This Last?
3.2 Major Success in the Pain Pharmaceutical Market Has Proved to Be Elusive to Date
3.3 While the Past Has Been Difficult for Pain Management, There is Optimism for the Future
4 The Global Non-Narcotics Market 2008-2023
4.1 Non-Narcotics Market Analysis
4.2 Efferalgan Currently Leads the Non-Narcotics Market – But Will This Last?
4.2.1 Development of Efferalgan (Paracetamol)
4.3 Tylenol Set to Reach Blockbuster Status
4.3.1 Development of Tylenol (Paracetamol)
4.4 Aspirin Bayer - Huge Amount of Line Extensions Keeping Sales Up
4.4.1 Aspirin Bayer (Acetylsalicylic Acid)
4.5 Advil Set to Exhibit Strong Growth?
4.5.1 Advil (Ibuprofen)
4.6 Tramal – How Will Sales Develop?
4.6.1 Development of Tramal (Tramadol)
4.7 The Non-Narcotics Market Currently Dominates the Pain Industry
5 The Global Narcotics Market 2008-2023
5.1 Narcotics Market Analysis
5.2 Oxycontin – Beset by Major Challenges
5.2.1 Development of Oxycontin (Oxycodone)
5.3 Duragesic
5.3.1 Development of Duragesic (Fentanyl)
5.4 Oxycodone TEVA
5.4.1 Oxycodone
5.5 Fentanyl MYLA – How Will Sales Develop?
5.5.1 Fentanyl
5.6 Fentanyl NOVT – How Will Sales Develop?
5.7 Total Sales in the Narcotics Market Will Increase Despite Being Crowded
6 The Global Anti-Arthritic Market 2008-2023
6.1 Anti-Arthritic Market Analysis
6.2 Pfizer's Celebrex Dominates the Market, But Will This Last?
6.2.1 Development of Celebrex (Celecoxib)
6.3 Voltaren – How Will Sales Develop?
6.3.1 Development of Voltaren (Diclofenac)
6.4 Arcoxia Has Reduced Gastro Intestinal Effects
6.4.1 Development of Arcoxia (Etoricoxib)
6.5 Mobic Will Suffer from Generic Competition
6.5.1 Development of Mobic (Meloxicam)
6.6 Arthrotec Will Decline in Growth
6.6.1 Development of Arthrotec (Diclofenac/Misoprostol)
6.7 Rises Predicted for Global Arthritis Market
7 The Global Anti-Migraine Market 2008-2023
7.1 Anti-Migraine Market Analysis
7.2 GSK's Blockbuster Imitrex/Imigran – How Will Sales Develop?
7.2.1 Development of Imitrex/Imigran (Sumatriptan)
7.3 Merck & Co's Maxalt - The New Market Leader Perhaps?
7.3.1 Development of Maxalt (Rizatriptan)
7.4 Zomig Shows Positive Growth
7.4.1 Development of Zomig (Zolmitriptan)
7.5 Relpax – How Will Sales Develop?
7.5.1 Development of Relpax (Eletriptan)
7.6 Naramig – How Will Sales Develop?
7.6.1 Development of Naramig (Naratriptan)
7.7 What Does the Future Hold for Migraine Therapy?
7.8 What are the Unmet Needs in the Management of Migraine
8 SWOT Analysis
8.1 SWOT Analysis of the Global Pain Market
8.2 Market Drivers
8.3 Market Restraints
8.4 The Pain Market Suffered After the Withdrawal of COX-2 Inhibitors
8.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs
8.6 Patients Dependent on Reformulations of Existing Drugs
8.7 The Narcotics Market Suffers from Serious Side Effects
8.8 The Under-Treatment of Pain
8.9 How Might These Findings Affect the Market for Pain Drugs?
8.10 The Future of the Pain Market - Closing Comments
8.10.1 Shortcomings in the Attitude Towards Pain Management Illustrate the Need for the Proper Use of New and Existing Pain Management Therapies
8.10.2 Analgesic Effect of Established Drugs for Other Diseases Will Continue to be of Relevance to the Pain Management Market
8.10.3 Personalised Pain Management Therapy
9 Pipeline Products for the Treatment of Pain
9.1 The Pipeline in the Pain Market is Large and Expanding
9.2 The Potential of the Pain Market Has Encouraged R&D Efforts
9.3 Innovation Rules for Early-Stage Pipeline Drugs
9.4 Late-Stage Pipeline Products in the Non-Narcotics Market
9.5 Late-Stage Pipeline Products in the Narcotics Market
9.6 Late-Stage Pipeline Products in the Anti-Arthritic Market
9.7 Late-Stage Pipeline Products in the Anti-Migraine Market
9.8 The Pain Pipeline Shows Short- and Long-Term Potential
10 Future Therapies
10.1 Cannabinoids and Pain: An Alternative to Opioids?
10.2 Experimentally Induced Acute Pain
10.3 Post Surgical Acute Pain
10.4 Chronic Pain
10.5 Sativex
10.5.1 European Phase III Trials of Sativex
10.5.2 Sativex Approved for Cancer Pain
10.6 Cannabinoids and Pain: a Lucrative Market?
10.7 The Future of Pain Research
10.8 Advanced Drug Delivery
10.8.1 Delivery of Poorly-Soluble Drugs
10.8.2 Examples of Poorly-Water-Soluble Drugs
11 Conclusions
11.1 The Pain Market is Heading for Consistent Financial Growth
11.2 Will the Non-Narcotics Segment Dominate the Pain Market in Future?
11.3 The Narcotics Market Will be Hampered by Controversial Issues
11.4 The Anti-Arthritic Market Shows No Signs of Slowing Down
11.5 The Anti-Migraine Market Will Suffer Due to Patent Expiry of Key Products
11.6 Major Success in the Pain Pharmaceutical Market Has Proved to Be Elusive to Date
11.7 Why Growth in the Pain Market Will Continue
List of Tables
Table 3.1 The Global Pain Pharmaceutical Market Forecast ($m), 2008-2023
Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for the Leading Pain Markets, 2007 & 2013
Table 3.3 Top Ten Products in the Pain Market ($m), 2007
Table 4.1 The World Non-Narcotics Market ($m) Forecast 2008-2023
Table 5.1 The World Narcotics Market ($m) Forecast 2008-2023
Table 6.1 The World Anti-Arthritic Market ($m) Forecast 2008-2023
Table 7.1 The World Anti-Migraine Market ($m) Forecast 2008-2023
Table 8.1 A SWOT Chart for the Pain Market, 2008-2013
Table 9.1 Late-Stage Non-Narcotic Pipeline Drugs for Pain, 2008
Table 9.2 Late-Stage Narcotic Pipeline Drugs for Pain, 2008
Table 9.3 Late-Stage Anti-Arthritic Pipeline Drugs for Pain, 2008
Table 9.4 Late-Stage Anti-Migraine Pipeline Drugs for Pain, 2008
List of Figures
Figure 3.1 The Global Pain Pharmaceutical Market Revenue Forecast ($m), 2008-2023
Figure 3.2 Leading Pain Markets’ Revenue ($m) Comparison, 2007 & 2013
Figure 3.3 Leading Pain Sectors’ Market Share (%), 2007
Figure 3.4 Leading Pain Sectors’ Market Share (%), 2013
Figure 4.1 Non-Narcotics World Market Revenue Forecast ($m), 2008-2023
Figure 4.2 Efferalgan Revenue Forecast ($m), 2008-2023
Figure 4.3 Tylenol Revenue Forecast ($m), 2008-2023
Figure 4.4 Aspirin Bayer Revenue Forecast ($m), 2008-2023
Figure 4.5 Advil Revenue Forecast ($m), 2008-2023
Figure 4.6 Tramal Revenue Forecast ($m), 2008-2023
Figure 5.1 Narcotics World Market Revenue Forecast ($m), 2008-2023
Figure 5.2 Oxycontin Revenue Forecast ($m), 2008-2023
Figure 5.3 Duragesic Revenue Forecast ($m), 2008-2023
Figure 5.4 Oxycodone TEVA Revenue Forecast ($m), 2008-2023
Figure 5.5 Fentanyl MYLA Revenue Forecast ($m), 2008-2023
Figure 5.6 Fentanyl NOVT Revenue Forecast ($m), 2008-2023
Figure 6.1 Anti-Arthritic World Market Revenue Forecast ($m), 2008-2023
Figure 6.2 Celebrex Revenue Forecast ($m), 2008-2023
Figure 6.3 Voltaren Revenue Forecast ($m), 2008-2023
Figure 6.4 Arcoxia Revenue Forecast ($m), 2008-2023
Figure 6.5 Mobic Revenue Forecast ($m), 2008-2023
Figure 6.6 Arthrotec Revenue Forecast ($m), 2008-2023
Figure 7.1 Anti-Migraine World Market Revenue Forecast ($m), 2008-2023
Figure 7.2 Imitrex/Imigran Revenue Forecast ($m), 2008-2023
Figure 7.3 Maxalt Revenue Forecast ($m), 2008-2023
Figure 7.4 Zomig Revenue Forecast ($m), 2008-2023
Figure 7.5 Relpax Revenue Forecast ($m), 2008-2023
Figure 7.6 Naramig Revenue Forecast ($m), 2008-2023
Figure 11.1 The Global Pain Pharmaceutical Market Revenue Forecast ($m), 2008-2023